La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Bowman Consulting Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Bowman Consulting Group..

Bowman Consulting Group (NASDAQ:BWMN) Azioni, Catena delle Opzioni

Bowman Consulting Group

Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.

Bowman Consulting Group Ltd. - Common Stock

Bowman Consulting Group Ltd

BP P.L.C. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) shares are trading higher Monday following a report suggesting Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) is considering acquiring the company.
What To Know: According to <a href="https://www.bloomberg.com/news/articles/2025-05-05/bp-rises-after-shell-is-said-to-study-merits-of-an-acquisition?embedded-checkout=true">Bloomberg</a>, Shell is evaluating a potential acquisition of BP, but waiting for further stock and oil price declines before making a final decision.
Other companies are also reportedly evaluating whether to pursue an acquisition of BP.
Shell has been in discussions with its advisors regarding a possible deal. Shell may choose to focus on buybacks and smaller acquisitions.
When asked about the report, a Shell spokesperson said, "As we have said many times before, we are sharply focused on capturing the value in Shell through continuing to focus on performance, discipline and simplification."
See Also: <a href="https://www.benzinga.com/general/health-care/25/05/45202124/humana-elevance-aetna-face-doj-lawsuit-over-illegal-kickback-scheme-discrimination-against-disabled-people">Humana, Elevance, Aetna Face DOJ Lawsuit Over Illegal Kickback Scheme, Discrimination Against Disabled People</a>
BP Price Action: At the time of writing, BP shares are trading 3.49% higher at $29.10, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

News

Movers

SHEL

BP Stock Jumps On Report of Possible Acquisition by Shell

UBS analyst Thomas Wadewitz maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Neutral and lowers the price target from $30 to $27.

Price Target

Analyst Ratings

WERN

UBS Maintains Neutral on Werner Enterprises, Lowers Price Target to $27

UBS analyst Douglas Harter maintains Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) with a Neutral and raises the price target from $38 to $40.

UBS Maintains Neutral on Enact Holdings, Raises Price Target to $40

UBS analyst Jay Sole maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Buy and raises the price target from $68 to $72.

BIRK

UBS Maintains Buy on Birkenstock Holding, Raises Price Target to $72

Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) could highlight the launch of a lower-priced Lucid Gravity vehicle and share how tariffs impact the company when the electric vehicle company reports first-quarter financial results after the market closes on<a href="https://www.benzinga.com/earnings"> Tuesday.</a>
Here is a look at analyst earnings estimates and key items to watch.
Earnings Estimates: Analysts expect Lucid to report first-quarter revenue of $250.0 million, up from $172.7 million in last year's first quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in four straight quarters, beating estimates in only those four quarters out of the last ten quarters overall.
Analysts expect Lucid to report a loss of 23 cents per share in the quarter, an improvement from 30 cents per share in last year's first quarter.
The company has beaten analyst estimates for earnings per share in two straight quarters and four of the last 10 quarters.
Read Also: <a href="https://www.benzinga.com/25/04/44802015/us-electric-vehicle-sales-up-11-in-q1-as-tesla-declines-the-winners-and-losers">Tesla Loses Steam In Q1 While US EV Sales Climb: The Winners And Losers</a>
Key Items to Watch: Lucid previously reported first-quarter deliveries of 3,199 vehicles, a company record and up 58% year over year.
The first quarter&#8217;s delivery momentum continued a strong 2024, which saw the company post four consecutive quarters of record deliveries.
The company&#8217;s guidance calls for the production of 20,000 vehicles in 2025. Analysts and investors will be looking to see if this guidance remains in place and if the company shares details on delivery guidance for 2025.
Lucid <a href="https://www.benzinga.com/25/04/44825160/whats-going-on-with-lucid-group-stock-on-tuesday">recently unveiled the</a> 2026 Lucid Gravity SUV, a three-row electric vehicle that could better compete with Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and other EV SUV makers. The new version starts at $94,900 with a lower-priced model expected to start at $79,900 and hit the market later this year.
Investors and analysts will be looking for more commentary on the impact of tariffs on Lucid. Interim CEO Marc Winterhoff previously said the company will be affected by tariffs and is taking steps to lower the impact.
While tariffs could be negative for Lucid, one positive that could get traction in the earnings report and commentary is potential market share gains from rival Tesla.
Winteroff <a href="https://www.benzinga.com/25/03/44570246/whats-going-on-with-lucid-stock-today">previously said that</a> Lucid was seeing a sharp increase in orders for vehicles from former Tesla owners, which comes as some have grown tired of CEO Elon Musk's push into politics. Tesla vehicles have also been the subject of increased vandalism.
LCID Price Action: Lucid stock is down 5.75 to $2.38 on Monday versus a 52-week trading range of $1.93 to $4.43. Lucid stock is down 21.3% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Photo: Shutterstock

Earnings

Previews

LCID

TSLA

Lucid Q1 Earnings Preview: Lower-Priced Vehicles, Tariff Concerns, Market Share Gains From Tesla, Top Items To Watch

UBS analyst Alex Kramm maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Neutral and raises the price target from $235 to $245.

CBOE

UBS Maintains Neutral on Cboe Global Markets, Raises Price Target to $245

UBS analyst Rodrigo Alcantara maintains Coca-Cola Femsa SAB de (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) with a Buy and raises the price target from $106 to $109.

UBS Maintains Buy on Coca-Cola Femsa SAB de, Raises Price Target to $109

Despite the old market adage &#8220;Sell in May and go away,&#8221; historical data tells a different story — May has actually been a profitable month for the U.S. stock <a href="https://www.benzinga.com/25/04/45115442/sell-in-may-and-go-away-looks-outdated-as-mayjuly-data-signal-bullish-sp-500-seasonality">market in recent decades.</a>
Over the past 20 years, the S&amp;P 500 — tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — has posted an average return of 0.6% in May, finishing the month in the green 15 out of 20 times. 
The most substantial gains were recorded in May 2008, up 5.9%, and May 2024, up 5.1%, while the worst performance came in May 2010, with an 8% drop.
Several S&amp;P 500 stocks have consistently outperformed during May, with average returns well above the broader index. Here are five standout names with at least 5% average May returns over the past two decades.
<h3 class="wp-block-heading">5) Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</h3>
<ul>
<li>Average May return: +5.8%</li>
<li>Winning ratio: 60%</li>
<li>Best May performance: +29.7% (2014)</li>
<li>Worst May performance: -20.8% (2012)</li>
<li>Next earnings release: July 16, 2025</li>
<li>Notable trend: May is Netflix's third-best performing month after January (14.7%) and October (6.94%).</li>
</ul>
<h3 class="wp-block-heading">4) McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)</h3>
<ul>
<li>Average May return: +6.35%</li>
<li>Winning ratio: 90%</li>
<li>Best May performance: +17.9% (2017)</li>
<li>Worst May performance: -9.1% (2018)</li>
<li>Next earnings release: May 8, 2025</li>
<li>Notable trend: Currently riding a 6-year winning streak in May, and it&#8217;s historically McKesson&#8217;s best month of the year.</li>
</ul>
<h3 class="wp-block-heading">3) Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)</h3>
<ul>
<li>Average May return: +6.58%</li>
<li>Winning ratio: 85%</li>
<li>Best May performance: +22.1% (2017)</li>
<li>Worst May performance: -18.3% (2012)</li>
<li>Next earnings release: May 15, 2025</li>
<li>Notable trend: The company has delivered gains in each of the past 12 Mays, making it the strongest month for the stock historically.</li>
</ul>
<h3 class="wp-block-heading">2) Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</h3>
<ul>
<li>Average May return: +7.81%</li>
<li>Winning ratio: 70%</li>
<li>Best May performance: +38.4% (2017)</li>
<li>Worst May performance: -25.16% (2019)</li>
<li>Next earnings release: May 28, 2025</li>
<li>Notable trend: May ranks as Nvidia's second-best month, just behind August, up 8.2%.</li>
</ul>
<h3 class="wp-block-heading">1) Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</h3>
<ul>
<li>Average May return: +6.58%</li>
<li>Winning ratio: 60%</li>
<li>Best May performance: +41.8% (2013)</li>
<li>Worst May performance: -17.4% (2012)</li>
<li>Next earnings release: May 6, 2025</li>
<li>Notable trend: May is AMD's second-strongest month, trailing only November at 9.5%. </li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45201761">Palantir Smokes S&amp;P 500 Peers With 393% Rally But Overheated Technicals Raise Red Flag Ahead Of Earnings</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

NFLX

NVDA

TTWO

S&P 500 Stocks That Defy 'Sell In May' Myth: 5 Companies With Strong Historical Gains

UBS analyst Douglas Harter maintains Radian Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDN#NYSE">RDN</a>) with a Neutral and raises the price target from $34 to $36.

UBS Maintains Neutral on Radian Group, Raises Price Target to $36

BioNTech SE&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)&nbsp;on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $2.02</a>.
The COVID-19 vaccine maker reported sales of $192.23 million (182 million euros), compared to 187 million euros, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190192/biontech-announces-first-quarter-2025-financial-results-and-corporate-update" rel="noreferrer noopener">the consensus of $177.40 million</a>.
Revenues during the first quarter of 2025 were mainly driven by revenues derived from BioNTech&#8217;s COVID-19 vaccine collaboration.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44535393/european-patent-office-rules-vaccine-developer-curevacs-amended-patent-valid-stock-jumps" rel="noreferrer noopener">European Patent Office Rules Vaccine Developer CureVac&#8217;s Amended Patent Valid, Stock Jumps</a>
&#8220;Our revenues for the first quarter reflect the seasonal demand for COVID-19 vaccines and are in line with our expectations,&#8221;&nbsp;said Jens Holstein, CFO of BioNTech. &#8220;BioNTech&#8217;s robust financial position empowers us to pursue our strategic goal of evolving into a leading biotech company with multiple oncology products by 2030.&#8221;
Cost of sales was 83.8&nbsp;million euros compared to 59.1&nbsp;million&nbsp;a year ago, mainly due to a positive impact of an inventory revaluation in the first quarter of 2024.
Research and development expenses were 525.6&nbsp;million euros compared to 507.5&nbsp;million euros a year ago. The increase was mainly driven by progressing late-stage clinical studies for candidates in BioNTech&#8217;s ADC and antibody portfolio.
Cash and cash equivalents plus security investments&nbsp;as of March&nbsp;31, 2025, reached 15.85 billion euros.
<h2 class="wp-block-heading">CFO Appointment</h2>
BioNTech appointed Ramón Zapata-Gomez to the Management Board on Monday as Chief Financial Officer, effective July 1, 2025. He will join BioNTech from Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) global biomedical research organization, where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45189869/biontech-announces-appointment-of-ram-n-zapata-to-management-board-as-chief-financial-officer" rel="noreferrer noopener">on June 30, 2025</a>.
<h2 class="wp-block-heading">Guidance For 2025</h2>
BioNTech <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44220746/pfizers-covid-19-shot-partner-biontech-reports-q4-profit-but-2025-guidance-falls-short-on-expectations" rel="noreferrer noopener">reaffirmed its fiscal year 2025</a> guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.08 billion euros and revenue phasing similar to 2024, primarily concentrated in the last three to four months, driving the full-year revenue figure. The revenue guidance assumes:
<ul>
<li>Relatively stable vaccination rates, pricing levels, and market share compared to 2024.</li>
<li>Estimated inventory write-downs and other charges by BioNTech&#8217;s collaboration partner Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) that negatively influence BioNTech&#8217;s revenues.</li>
<li>Anticipated revenues from a pandemic preparedness contract with the German government.</li>
<li>Anticipated revenues from the BioNTech Group service businesses.</li>
<li>Potential changes to the law or governmental policy, including tariffs, public health policy, and evolving public sentiment worldwide, could further negatively impact our anticipated revenues and expenses.</li>
</ul>
BioNTech expects to focus investments on R&amp;D and scaling the business for late-stage development and commercial readiness in oncology while remaining cost-disciplined.
As part of BioNTech&#8217;s strategy, the Company may continue to evaluate appropriate corporate development opportunities to drive sustainable long-term growth and create future value.
Price Action: BNTX stock is down 3.65% at $101.11 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45200539/alibabas-ant-group-eyes-hong-kong-ipo-for-ant-international-as-it-pushes-forward-with-fintech-growth" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s Fintech Arm Ant Group Eyes Hong Kong IPO For Ant International</a></li>
</ul>
Photo Marcus Krauss via Shutterstock

Biotech

Guidance

Health Care

Management

Trading Ideas

General

BNTX

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

UBS analyst Douglas Harter maintains Redwood Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWT#NYSE">RWT</a>) with a Buy and raises the price target from $6.5 to $7.

UBS Maintains Buy on Redwood Trust, Raises Price Target to $7

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) will likely focus on the future launch of its R2 vehicle when presenting first-quarter financial results after<a href="https://www.benzinga.com/earnings"> market close Tuesday.</a>
Here are the earnings and revenue estimates, what analysts are saying ahead of the report and key items to watch.
Earnings Estimates: Analysts expect Rivian to report first-quarter revenue of $1.0 billion, down from $1.2 billion in last year's first quarter according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"> from Benzinga Pro.</a>
Rivian beat the analyst estimate for revenue in the fourth quarter and has beaten analyst estimates in seven of the last 10 quarters.
Analysts expect Rivian to report a first-quarter loss of 76 cents per share, an improvement from a loss of $1.24 in last year's first quarter.
Rivian beat the analyst estimate for earnings per share in the fourth quarter and has beaten analyst estimates in seven of the last 10 quarters.
Read Also: <a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla">These EV Makers Could Shine If Musk Leaves Tesla</a>
What Analysts Are Saying: Analysts have been lowering the price target on Rivian stock ahead of first-quarter financial results.
Piper Sandler analyst Alexander Potter <a href="https://www.benzinga.com/25/03/44423177/rivian-analyst-downgrades-stock-with-triple-whammy-of-policy-risk-no-catalysts-in-2025">downgraded the stock</a> from Overweight to Neutral and lowered the price target from $19 to $13.
The analyst said Rivian&#8217;s outlook in the coming years is favorable, but it faces a short-term outlook that won't excite investors and several potential negative headwinds.
Potter said Rivian has &#8220;no catalysts in 2025.&#8221;
&#8220;We struggle to identify upside catalysts in 2025. In 2026, investors can look forward to the R2 launch and (maybe) JV customer wins,&#8221; Potter said.
The analyst said the lower-priced R2 launch is vital to Rivian stock, but doesn't launch until 2026.
While Rivian gets downgraded, Potter noted the stock is Piper&#8217;s favorite Neutral-rated stock in the sector.
&#8220;We like Rivian&#8217;s strategy, particularly self-reliance in electronics and software.&#8221;
Potter said along with Rivian having no catalysts in 2025, the company faces a potential &#8220;triple-whammy&#8221; of policy risk that could happen in 2025 or beyond.
There are three policy risks to consider: the Trump administration could pull Rivian's Department of Energy loan funding; the $7,500 EV tax credit could be canceled; and CARB (California Air Resources Board) could lose the ability to regulate emissions, which could hurt credit revenue.
Here are other recent <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">analyst ratings on Rivian </a>and their price targets:
<ul>
<li>JPMorgan: Maintained Underweight rating, lowered price target from $11 to $10</li>
<li>Baird: Maintained Neutral rating, lowered price target from $16 to $14</li>
<li>Goldman Sachs: Maintained Neutral rating, lowered price target from $14 to $12</li>
<li>UBS: Maintained Neutral rating, lowered price target from $14 to $12</li>
<li>Mizuho: Maintained Neutral rating, lowered price target from $11 to $10</li>
</ul>
Key Items to Watch: Analysts could ask questions about Rivian&#8217;s recent addition to the board of directors. The appointment of Coherent Corp co-founder and CEO Aidan Gomez <a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration">as a board member</a> could signal a larger focus on AI.
Investors and analysts could be looking for more commentary on Rivian's technology and AI, which could be underappreciated given its current lower vehicle production than other competitors.
Rivian <a href="https://www.benzinga.com/25/04/44608286/why-ev-maker-rivian-automotives-stock-is-plunging-today">previously announced </a>8,640 vehicle deliveries in the first quarter, which was down 36.4% year-over-year. The company has reaffirmed its full-year 2025 delivery guidance of a range of 46,000 to 51,000 vehicles.
Analysts and investors will want to see this guidance maintained and would also love more color on an early look at 2026 delivery estimates with the R2 scheduled for deliveries in the first half of 2026.
Rivian previously announced it was opening up its delivery van orders to customers outside of early investor and partner Amazon.com Inc. The company recently announced it has<a href="https://www.benzinga.com/25/04/44859742/rivian-delivers-70-fleet-vehicles-to-hellofresh-after-ending-exclusive-amazon-deal"> signed a deal </a>with meal kit company HelloFresh for 70 Rivian vans to be added to its commercial vehicle fleet.
The electric vehicle company will likely be asked to comment on the impact tariffs and the new White House administration could have on upcoming production and deliveries. Rivian produces the majority of its vehicles in the United States, but it could be impacted by the end of tax credits for electric vehicles.
In recent interviews, Rivian CEO RJ Scaringe<a href="https://www.benzinga.com/trading-ideas/25/04/44598035/rivian-ceo-says-us-needs-more-under-50k-evs-to-catch-up-to-china-you-have-to-have-the-plumbing-right" target="_blank" rel="noopener"> has shown confidence </a>in the R2 launch and called for the EV sector to have more vehicles under the $50,000 price point. The R2 is expected to have a starting price of around $45,000.
Scaringe will likely share his belief that this vehicle launch is critical for Rivian's financial future and for the EV sector at large.
RIVN Price Action: Rivian stock is down 1.9% to $13.56 on Monday versus a 52-week trading range of $9.25 to $18.86. Rivian stock is up 2.8% year-to-date in 2025 and up 31.8% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/45014243/bezos-vs-tesla-vs-rivian-stock-company-backed-by-amazon-founder-can-turn-20k-ev-truck-into-suv">Bezos Vs. Tesla Vs. Rivian Stock? Company Backed By Amazon Founder Can Turn $20K EV Truck Into SUV</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Reiteration

RIVN

Rivian Q1 Earnings Preview: All Eyes On R2 Launch, Analyst Says 'No Catalysts In 2025'

Bank Of America Securities analyst Michael McGovern reaffirmed a Buy rating on DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a price forecast of $235 ahead of <a href="https://www.benzinga.com/quote/DASH/analyst-ratings" target="_blank" rel="noreferrer noopener">earnings release on 7th May</a>.
The analyst writes that BSM data indicates DoorDash&#8217;s growth decelerated 90bps sequentially in the first quarter (vs. consensus <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">estimate of deceleration of 160bps)</a>.
Also, the data reveals that April growth accelerated year over year by 110bps, despite the negative impact of Easter&#8217;s timing (Visible Alpha&#8217;s consensus of a 110bps deceleration for the second quarter), adds the analyst.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/04/45058659/dominos-is-fine-with-doordash-eyes-full-national-rollout-for-q2-ceo-says-pizza-giants-strategy-is-to-meet-customers-where-they-are" target="_blank" rel="noreferrer noopener">Dominos Is &#8216;Fine&#8217; With DoorDash, Eyes Full National Rollout For Q2: CEO Says Pizza Giant&#8217;s Strategy Is To &#8216;Meet Customers Where They Are&#8217;</a>
The analyst estimates GOV/EBITDA at $23 billion/$582 million, slightly above the Street consensus of $22.9 billion/$586 million.
McGovern estimates a 5.6% incremental EBITDA margin on GOV, with higher contribution of high-growth New Verticals.
The analyst cited key topics for the call, including ROO&#8217;s proposal, Western Europe competition, tariff impact, and regulations.
McGovern expects the second quarter GOV to be $23 billion-$23.4 billion and the EBITDA to be $580 million-$630 million.
The analyst anticipates typical management caution due to Easter timing (-1ppt growth), potential dollar weakness, and a focus on stronger EBITDA margin improvement in the second half.
Price Action: DASH shares are up 0.44% at $206 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45166629" target="_blank" rel="noreferrer noopener">Wendy&#8217;s Sizzles Abroad, But US Sales Leave Investors Cold</a></li>
</ul>
Image: Diego Thomazini, Shutterstock

DASH

DoorDash's Growth Picks Up Speed Despite Holiday Headwinds: Analyst

JPMorgan analyst Ryan Brinkman raised the price forecast for auto tech company Visteon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from $90 to $97.
Brinkman kept a Neutral rating following the company&#8217;s <a href="https://www.benzinga.com/quote/VC/analyst-ratings" target="_blank" rel="noreferrer noopener">first-quarter results reported in April</a>.
The company reported adjusted EPS of $2.40, which exceeded the $1.88 estimate, and sales of $934 million, which exceeded<a href="https://www.benzinga.com/pressreleases/25/04/n44974849/visteon-announces-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener"> the $910.98 million projection</a>.
The company withdrew full-year guidance, citing uncertainty <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">in the automotive industry</a>.
The analyst writes that the earnings showed slightly better revenue (+10% Growth over Market despite significant headwinds in China) and after adjusting for one-time commercial settlements, the underlying EBITDA still solidly beat expectations.
Despite withdrawn guidance, Brinkman raised the estimates thanks to strong new business <a href="https://www.benzinga.com/25/04/45059191/donald-trump-will-reduce-impact-on-us-auto-industry-by-alleviating-some-auto-tarrifs-report" target="_blank" rel="noreferrer noopener">and improved tariff regulations</a>.
Management hinted at updated guidance as visibility improves, which the analyst believes is now the case.
Overall, the analyst estimates EBITDA of $440 million (up from $435 million prior) for 2025, and $455 million (from $450 million prior) for 2026.
Brinkman says that the company is well-positioned to capitalize on the increasing integration of driver information systems and infotainment systems and the ongoing trend of fewer electronic control units facilitated by their SmartCore product.
Investors can gain exposure to the stock via&nbsp;First Trust SMID Capital Strength ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSCS#NASDAQ">FSCS</a>) and WisdomTree U.S. SmallCap Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EES#NYSE">EES</a>).
Price Action: VC shares are up 1.54% at $81.12 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45006138/smarter-cars-ahead-visteon-qualcomm-unveil-ai-cockpit-system" target="_blank" rel="noreferrer noopener">Visteon, Qualcomm Unveil AI Cockpit System For Smart Cars</a></li>
</ul>

Small Cap

Tech

FSCS

Visteon Navigates China Headwinds, Wins JPMorgan Analyst Nod

As a fast-food icon, McDonald's Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is structurally built for resisting recessionary conditions, offering nourishing meals and beverages conveniently and at relatively low prices. But even the Golden Arches couldn't overcome the unique <a href="https://www.benzinga.com/25/05/45159157/mcdonalds-ceo-the-us-economy-is-dividedlow-income-traffic-down-10-while-rich-diners-continue-to-spend">pressures of the current economic paradigm</a>. Nevertheless, market demand for MCD stock remains hot, facilitating a possible contrarian bullish opportunity.
Last Thursday, McDonald's released its first-quarter earnings report, which revealed <a href="https://www.benzinga.com/general/restaurants/25/05/45177147/mcdonalds-stumbles-on-weak-traffic-despite-margin-gains-and-analyst-optimism">disappointing sales trends</a> in both U.S. and international markets. Domestically, revenue fell 3.6% for the three months through March 2025, primarily due to weaker traffic from lower and middle-income groups. It should be noted, though, that spending from upper-income households remained strong.
On the international front, operations face headwinds as the management attempts to deliver value offerings and expand market share. Predictably, anti-American sentiment has risen in parts of Northern Europe and Canada. That, combined with the economic <a href="https://www.reuters.com/business/mcdonalds-global-sales-post-surprise-drop-tariff-chaos-hits-consumer-confidence-2025-05-01/">uncertainty</a> at home stemming from President Donald Trump's tariff policies, has taken a bite out of McDonald's financial performance.
Still, there are encouraging signs that shouldn't be ignored. Beyond the continued support of higher-income customers, McDonald's is seeing traction with its $5 meal deal, which will be extended through year-end.
On a much bigger level, President Trump — despite tough rhetoric — has <a href="https://www.benzinga.com/news/25/04/44886711/trump-expresses-reluctance-to-escalate-china-tariffs-hints-at-trade-deal">previously wavered on sustained, full-throttle tariffs</a>. This dynamic suggests that the White House is at least aware of the political consequences of a persistently downbeat economy. As such, it wouldn't be unreasonable to be contrarian on MCD stock in the hopes of cooler heads prevailing.
<h2 class="wp-block-heading">Betting On The Statistical Edge Of MCD Stock</h2>
Professional blackjack players often deploy a strategy called card counting. Basically, the idea is that in a standard, shuffled deck with no counting or manipulation, the house has a slight edge (typically around half-a-percent). However, under certain circumstances, the deck becomes hot — resulting in a higher proportion of high-value cards. This dynamic shifts the odds in the bettor's favor, incentivizing larger wagers.
Publicly traded securities often follow a similar logic. Under any given circumstances, a stock may have a baseline probability of long-side success. One can squabble over the details but for a typical blue chip, the odds a long position will be profitable in a week's time is about 51% to 52%. It's not nothing, but it's also not anything to get excited about.
That said, there are certain circumstances when the deck gets hot. When it does so, an incentive materializes to take an aggressive wager.
In the past 10 weeks, MCD stock printed a "6-4" sequence: six weeks of upside interspersed with four weeks of downside, with an overall net positive trajectory across the period. From a technical interpretation, MCD has shown a <a href="https://www.benzinga.com/general/restaurants/25/04/45113728/mcdonalds-technicals-show-appetite-for-more-gains-ahead-of-earnings">strong uptrend</a>, indicating robust momentum and buying strength.
What makes the demand sequence empirically significant, though, is that in 60.71% of the times the pattern flashes, MCD stock has popped higher in the following week. For context, MCD already favors long-side speculation, with the baseline one-week probability standing at around 56%.
With the deck being hot, traders have an opportunity to go against the implications of McDonald's disappointing first-quarter earnings report. It just might be the smarter move.
<h2 class="wp-block-heading">An Aggressive Strategy for a Stable Blue Chip</h2>
Based on historical trends following the 6-4 sequence, if the positive pathway materializes, MCD stock could hit a peak median price of over $323 over the next three weeks before tapering off. On the other end, should the bears win, MCD risks a gradual deflating until leveling off at around $313.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05144803/MCD-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-902033" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05144803/MCD-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05144803/MCD-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05144803/MCD-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05144803/MCD-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Considering the higher statistical likelihood of upside, aggressive speculators may consider the 320/322.50 bull call spread expiring May 16. This transaction involves buying the $320 call and simultaneously selling the $322.50 call, for a net debit paid of $116. Should MCD stock rise through the short strike price of $322.50 at expiration, the maximum reward stands at $134, a payout of 115.52%.
What makes this trade so aggressive — and thus so rewarding — is the narrow window of profitability. Currently, the trade's breakeven price is $321.16, about 1.43% above the time-of-writing price. Therefore, MCD stock must hit the mark or exceed for speculators to win.
Of course, the idea here is that empirically, the 6-4 sequence puts the odds in favor of the bettor. It doesn't guarantee anything. However, this trade leverages market intelligence, facilitating more confidence in the decision-making process.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45178663/smart-money-buys-anet-stock-call-options-bounce-signal">Options Corner: Smart Money Traders Charge In as Arista Networks Hits Potential Bounce Signal</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Options

Options Corner: McDonald's Signals A 'Hot Deck' For Aggressive Speculators

Sen. Rand Paul (R-KY) isn't buying President Donald Trump's latest explanation for how tariffs will benefit Americans. In fact, he's calling out what he sees as a major contradiction.
<h2 class="wp-block-heading">Tax Cuts to Soften Tariff Blow?</h2>
After Trump suggested cutting or even eliminating federal income taxes for Americans making under $200,000, Paul fired back on <a href="https://x.com/RandPaul/status/1916982342213574726">X</a>. Quoting a headline from <a href="https://thehill.com/business/domestic-taxes/5270339-trump-floats-income-tax-cut-to-ease-tariff-impact/">The Hill</a>, Paul wrote, &#8220;Wasn't the pro-tariff crowd trying to tell us tariffs wouldn't increase the cost of goods? Sure seems like an admission&#8230;&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wasn't the pro-tariff crowd trying to tell us tariffs wouldn't increase the cost of goods? Sure seems like an admission…<a href="https://t.co/vVk6PWZHCJ">https://t.co/vVk6PWZHCJ</a>
&mdash; Rand Paul (@RandPaul) <a href="https://twitter.com/RandPaul/status/1916982342213574726?ref_src=twsrc%5Etfw">April 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
In a Sunday <a href="https://truthsocial.com/@realDonaldTrump/posts/114410073592204291">post</a> on Truth Social, Trump floated the idea of income tax relief as a way to soften the blow of his aggressive trade policies. &#8220;When Tariffs cut in, many people's Income Taxes will be substantially reduced, maybe even completely eliminated,&#8221; he wrote. &#8220;Focus will be on people making less than $200,000 a year.&#8221;
Paul has been critical of Trump's approach to trade for years, and he doubled down in recent interviews.
&#8220;It's backwards and upside down,&#8221; Paul told <a href="https://www.youtube.com/watch?v=iuUECPxrjVU">CNBC</a> last month. &#8220;The fallacy is this: that somehow in a trade, someone must lose &#8230; that China's ripping you off or Japan's ripping you off.&#8221;
Trending: <a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a>
<h2 class="wp-block-heading">Paul Pushes Back on Tariff Logic</h2>
To Paul, trade is not a competition with winners and losers. It's cooperation. &#8220;Every trade that occurs in the marketplace is mutually beneficial,&#8221; he said. &#8220;If you want to sell me your coat and I give you $200 for it, we both agree to it and we're both happy with the trade.&#8221;
He added, &#8220;I have a trade deficit with my grocery store.&#8221;
Trump has leaned into a different view, framing international trade deficits as proof that the U.S. is being taken advantage of. &#8220;They ripped us off left and right. But now it's our turn to do the ripping,&#8221; he <a href="https://www.youtube.com/watch?v=oR3ouMYLPT8">said</a> at last month&#8217;s National Republican Congressional Committee dinner.
Paul isn't just poking holes in Trump's logic—he's also worried about the economic fallout. He said Trump's tariffs could hurt Americans' retirement savings and slow the economy. &#8220;The higher the trade deficits, the more prosperity. The lower the trade deficits, the less prosperity,&#8221; he said.
See Also: Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.
He also blasted Trump's math behind the tariff rates. According to Paul, the administration's so-called &#8220;reciprocal&#8221; tariffs are <a href="https://www.benzinga.com/markets/25/04/44678625/did-trump-team-manipulate-tariff-formula-to-achieve-higher-rates-experts-weigh-in-as-they-think-whole-thing-was-rigged">based on flawed calculations</a>.&nbsp;
Paul brought up Trump's frequent claim that Canada charges a <a href="https://www.benzinga.com/news/25/03/44326649/does-canada-really-have-a-250-tariff-in-place-on-us-dairy-products-imported-into-canada-here-are-the-facts">270% tariff on U.S. dairy</a> products. &#8220;Well, you know what the real tariff is? Zero,&#8221; Paul said.
While <a href="https://www.benzinga.com/markets/equities/25/04/45027881/trumps-approval-plummets-as-tariffs-bite-americans-expect-skyrocketing-prices-and-shrinking-wallets">polls show</a> that the majority of Americans expect Trump's tariff policies to raise consumer prices, Trump maintains that his strategy is delivering results. He claims new factories and jobs are being created and calls the shift a &#8220;BONANZA FOR AMERICA.&#8221;
Paul, meanwhile, remains unconvinced. &#8220;We have to start talking about the truth,&#8221; he told CNBC.
Read Next:
<ul>
<li>Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

'Sure Seems Like An Admission'—Rand Paul Asks, 'Wasn't The Pro-Tariff Crowd Trying To Tell Us Tariffs Wouldn't Increase The Cost Of Goods?'

If you have been around the energy markets long enough, you know crude oil has a flair for the dramatic.
When it sells off, it does not just trickle down; it falls off a cliff.
The rebound is vicious, fast and usually overdue when it finally wakes up. The trick, as always, is understanding the cycles, not panicking in the downtrend, and positioning for the inevitable rebound.
That is especially true for one of my favorite corners of the energy market: mineral royalty trusts and non-operator oil and gas interests. These are the little guys who do not drill a thing but still get paid when the oil flows.
All this is happening again right now. 
It's setting you up for the best income trade in a decade.
Let us walk through the big oil busts of the last few decades in the late 1990s: the 2008 crash, the 2014 to 2016 wipeout, and, of course, the COVID collapse of 2020.
I want to talk about what happened, how long sentiment stayed sour and what eventually got prices off the mat. Then, we will dig into what all that meant for the royalty trusts and non-operators and how their dividends held up (or not), how the market treated them, and what happened when oil came roaring back.
<h2 class="wp-block-heading">1998: The Asian Flu And The $10 Barrel</h2>
In the late 1990s, OPEC had a problem. They pumped too much oil, thinking Asia would keep consuming it. However, when the Asian financial crisis hit, demand cratered, inventories ballooned, and prices dropped like a rock.
Brent went as low as $10, and nobody wanted to touch an oil stock with a ten-foot pole.
Royalty trusts got smashed. Cash flows dried up, distributions were cut, and unit prices plunged. Investors were left staring at trailing yields in the teens, but those payouts were not sticking around.
Most trusts saw 50% or more wiped off their market capitalizations. However, by late 1999, OPEC got its act together and cut production. Inventories fell, demand slowly came back, and oil doubled. Royalty trust distributions rebounded quickly, and anyone who had the courage to buy when it all looked hopeless got rewarded in a big way.
<h2 class="wp-block-heading">2008: Peak Oil Euphoria Meets Lehman Brothers</h2>
By mid-2008, oil was $147 a barrel and people were chanting "peak oil" like it was gospel.
Then, the financial system imploded.
Demand evaporated, oil crashed to $30 and panic spread. Trust distributions went over the cliff.
Sabine Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBR#NYSE">SBR</a>) cut payouts by more than 50% in a single month.
Prices followed. These income names saw unit values drop 70% or more.
Yields were sky-high on paper, showing 20% or even 30%, but those were based on past payouts that had already been slashed. For most of 2009, distributions were a shadow of their former selves.
However, when the smoke cleared, oil demand returned, OPEC slashed production, and oil started climbing again. Trust distributions bounced, unit prices doubled or tripled off the lows and yields normalized in the high single digits.
Patience paid off.
<h2 class="wp-block-heading">2014 To 2016: The Shale Tsunami</h2>
This one was different. It was not a demand crash. It was too much U.S. shale oil.
OPEC got tired of losing market share and let prices fall from $115 in mid-2014 to under $30 by early 2016. Oil was in freefall for almost two years.
That stretched the pain out.
It was Drill, Baby, Drill Gone Bad, The Prequel.
Royalty and non-op names bled out slowly. Distributions did not collapse all at once&#8230;they just shrank quarter by quarter.
Permian Basin Royalty Trust's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBT#NYSE">PBT</a>) payout dropped by two-thirds.
PrairieSky (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PREKF#OTC">PREKF</a>) and Freehold slashed their dividends.
The market priced them accordingly.
Yields dropped, unit prices got hammered, and by 2016, it was hard to find anyone still bullish.
Then OPEC and Russia teamed up and finally cut production in late 2016.
By 2017, oil was back in the $60s, and royalty trusts started increasing dividends again.
Trusts that had lost 70% of their value doubled or more over the next 18 months. Investors who stayed the course got paid.
<h2 class="wp-block-heading">2020: The Pandemic Panic And Negative Oil Prices</h2>
Then came COVID. Demand did not just shrink. It vanished.
Planes stopped flying, cars stopped driving, and suddenly, the world was drowning in oil.
Saudi Arabia and Russia decided to have a price war on top of it all, and in April 2020, WTI futures went negative.
Royalty trusts had a rough time. Distributions were suspended.
Permianville (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVL#NYSE">PVL</a>) went 13 months without a single payout.
PrairieSky slashed its dividend by two-thirds.
Investors fled. Unit prices dropped 60% to 80% in weeks.
Trailing yields? Meaningless. Nobody was paying anything.
However, it did not last.
OPEC+ made historic cuts.
Demand started recovering.
When vaccines arrived in late 2020, the game changed. By mid-2021, Permianville was paying again. PrairieSky and Freehold started raising dividends.
Share prices doubled or tripled.
By 2022, Sabine's distribution hit $8.65, a monster rebound.
<h2 class="wp-block-heading">What It All Means</h2>
These downturns tell the same story every time: oil crashes, royalty and non-operator income disappear, and the market throws these stocks in the trash. Yields spike on trailing numbers, then vanish when dividends get cut. Sentiment stays ugly for too long.
However, when the oil price recovers, and it always has, these names come back fast. Distributions climb, unit prices follow, and investors who bought when everyone else was scared end up with huge yields on cost and big capital gains.
They are not for the faint of heart. You have to be willing to hold when there is blood in the oil patch.
It's a pain trade.
However, if you buy these things when oil is hated and the checks have stopped, you set yourself up for some of the most explosive total returns in the market.
This is deep value investing, oilfield-style.
And now, it's happening again.
Read the headlines:
<ul>
<li>OPEC is going to increase production.</li>
<li>Oil demand forecasts are being cut.</li>
<li>The much more energy-efficient AI from China will slash demand even further.</li>
<li>Nuclear energy plants are going to pop up like mushrooms with no regulatory delays or cost overruns and be built faster than Buc-ee's.</li>
<li>China will never import another drop of oil.</li>
</ul>
Negative sentiment is building, we&#8217;ve seen some distribution cuts and optimism is harder to find than a good book in a Blockbuster.
Royalty trusts and nonowner operators may go down before they go up, but when they do, they are going to go up a lot.
Those who buy in scale, with patience and a dash of courage, will be well rewarded.
<h2 class="wp-block-heading">Risk, Reward &amp; Reversals: Tactical Options Strategies for an Unstable Market</h2>
When markets get unpredictable, disciplined options strategies can give you an edge. Join Ryan Faloona, Anne-Marie Baiynd and Tim Melvin live on May 6 to learn how they're using risk reversals, 0DTE plays, and hedging tactics to stay nimble and generate income. Save your spot now to learn how to trade smarter this week.
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

PREKF

OPEC Just Created The Income Trade Of The Decade

Zimmer Biomet Holdings, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) reported first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the Street estimates of $1.77</a>.
The orthopedic giant reported sales of $1.91 billion, up 1.1% on a reported basis (+2.3% on constant currency), almost in line with the <a href="https://www.benzinga.com/pressreleases/25/05/n45189888/zimmer-biomet-announces-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">consensus of $1.9 billion</a>.
<ul>
<li>Knee product sales increased 0.6% to $792.9 million (+1.9%), and hip product sales increased 0.9% (+2.4% on constant currency) to $495.8 million.</li>
<li>Sports Medicine products generated sales of $470.5 million, up 3.9% (+4.9%).</li>
<li>Technology &amp; Data, Bone Cement, and Surgical sales fell 4.7% (-3.5%) to $149.9 million.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
Operating margin improved to 15.3% from 14.1%.
Ivan Tornos, Zimmer Biomet&#8217;s President and CEO, addressed &#8220;the recently completed <a href="https://www.benzinga.com/pressreleases/25/04/n44896156/zimmer-biomet-completes-acquisition-of-paragon-28" target="_blank" rel="noreferrer noopener">acquisition of Paragon 28</a>.&#8221; The company also updated its full-year 2025 reported revenue guidance to include tariff proposals and <a href="https://www.benzinga.com/news/guidance/25/01/43297796/zimmer-biomet-snaps-up-paragon-28-in-1-2-billion-deal-details" target="_blank" rel="noreferrer noopener">currency expectations</a>.
The company expects fiscal year 2025 adjusted EPS of $7.90-$8.10, down from <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43539408/why-is-zimmer-biomet-stock-trading-lower-on-thursday" rel="noreferrer noopener">prior guidance of $8.15-$8.35</a> versus consensus of $8.19.
The company expects 2025 revenue growth of 5.7% &#8211; 8.2% compared to 1%-3.5% expected earlier.
It expects a foreign currency exchange impact of 0.0%-0.5%.
In March, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Persona&nbsp;Revision SoluTion Femur, a revision knee implant&nbsp;component offering an alternative for patients with sensitivities to certain metals. Persona Revision SoluTion Femur will be commercially <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44187963/zimmer-biomet-receives-fda-clearance-for-persona-revision-solution-femur" rel="noreferrer noopener">available in the U.S. in Q3 2025</a>.
In April, Zimmer Biomet&#8217;s RibFix Advantage Fixation System received CE Mark certification – the first CE Mark for an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44582315/zimmer-biomet-receives-ce-mark-approval-for-ribfix-advantage-fixation-system" rel="noreferrer noopener">intrathoracic rib fixation system</a>.
Price Action:&nbsp;ZBH stock is down 9.57% at $92.59&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45196924/neurology-focused-axsome-therapeutics-clocks-around-60-topline-growth-in-q1-commercial-availability-of-newly-approved-migraine-drug-expected-in-june" target="_blank" rel="noreferrer noopener">Axsome Therapeutics Clocks Around 60% Topline Growth In Q1</a></li>
</ul>

Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) announced Monday that it partnered with Jumio to integrate Jumio ID Verification into their mobile app, streamlining check-in and reducing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45189279/alaska-airlines-partners-with-jumio-to-provide-faster-more-efficient-travel" rel="noreferrer noopener">hassle for international travelers</a>.
This allows international travelers with U.S. and Canadian passports to verify their identity in real time, bypassing check-in lines.
Jumio&#8217;s AI-powered solution supports over 5,000 ID subtypes globally, ensuring reliable and comprehensive verification.
Natalie Bowman, vice president of digital experience at Alaska Airlines, added, &#8220;Through this partnership, guests can verify their travel documents directly in their Alaska Airlines app, saving time in the airport lobby and at their gate.&#8221;
Bala Kumar, chief product and technology officer at Jumio, added, &#8220;We are proud to partner with Alaska Airlines to help travelers save time at the airport and to drive adoption rates for self-service ID verification,&#8221;&nbsp;
In April, the company reported&nbsp;first-quarter&nbsp;sales&nbsp;growth of 41% year over year (Y/Y) to $3.14 billion, which missed<a target="_blank" href="https://www.benzinga.com/25/04/44976464/alaska-air-hit-by-demand-dip-in-q1-loss-skips-fy25-guidance-update-amid-uncertainty" rel="noreferrer noopener"> the street view of&nbsp;$3.17 billion</a>.
Adjusted EPS loss&nbsp;of 77 cents, missed&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus loss of&nbsp;74 cents</a>. The loss reflects a softening demand environment and macroeconomic factors.
Alaska Air stock is trading higher on Monday on account of a drop in crude oil price, which reduces the input cost for airlines.
Investors can gain exposure to the stock via&nbsp;Avantis U.S. Small Cap Value ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVUV#NYSE">AVUV</a>) and U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>)
Price Action: ALK shares are up 4.16% at $48.95&nbsp;at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45020724/airlines-face-significant-pressure-analysts-adjust-expectations-after-q1-results" target="_blank" rel="noreferrer noopener">Airlines Face &#8216;Significant Pressure&#8217;: Analysts Adjust Expectations After Q1 Results</a></li>
</ul>
Photo via Shutterstock

Contracts

AVUV

JETS

Alaska Airlines Taps Jumio's AI for Frictionless International Travel

<a href="https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE">https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE</a>
President Donald Trump will sign an executive order Monday to streamline regulations surrounding pharmaceutical manufacturing in the United States, according to two White House officials who spoke on the condition of anonymity to describe plans that have not been made public.
The order to incentivize domestic drug manufacturing comes ahead of possible <a href="https://www.washingtonpost.com/business/2025/04/10/tariffs-pharmaceuticals-us-drugs-cost/">tariffs on pharmaceuticals</a> — a policy that's on hold, for now, pending an investigation by the Commerce Department to determine whether importing pharmaceuticals is a threat to national security. That Section 232 investigation could be completed this summer, one of the officials said Monday.
But regardless of whether the Trump administration puts tariffs on prescription drugs, Monday's executive order seeks to incentivize more domestic manufacturing of medications.

MRNA

'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

Press Releases

Bowman Awarded Multi-Year Contract by City of Montebello for On-Call Engineering Services

Bowman to Attend Two Investor Conferences in March

Bowman Awarded Construction Oversight Contract by City of Wenatchee

Bowman Announces Record Results for Fourth Quarter and Full Year 2024

Bowman Secures $3.8M in Water Resource Contracts

Bowman Awarded $2.2M Contract for ADA Design in Philadelphia

Bowman Appoints Virginia L. Grebbien to Board of Directors

Bowman Announces Dates for First Quarter 2025 Earnings Release and Webcast

Bowman Awarded $4.2 Million Transportation Contract in Illinois

Bowman Announces Attendance at May Investor Conferences

BWMN

Arcosa

Argan

Ameresco

Concrete Pumping Holdings, Inc. - Common Stock

Concrete Pumping Holdings

Cadeler A/S American Depositary Share (each representing four (4) Ordinary Shares)

Comments

Bowman Consulting Group

Bowman Consulting Group (BWMN) Opzioni

Bowman Consulting Group (NASDAQ:BWMN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO